ArticleCell metabolism2018
Isotope Tracing of Human Clear Cell Renal Cell Carcinomas Demonstrates Suppressed Glucose Oxidation In Vivo.
Open access · bronzeAbstract read
In one paragraph
Article in Cell metabolism, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 197 papers.
0numbers the graph read from it
0cells of the map it votes in
197citing papers in PubMed
10.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
197 citing papers in PubMed, 286 citations in OpenAlex.
- Local production of lactate, ribose phosphate, and amino acids within human triple-negative breast cancer.Med (New York, N.Y.) · 2021Trial
- Does Tumor FDG-PET Avidity Represent Enhanced Glycolytic Metabolism in Non-Small Cell Lung Cancer?The Annals of thoracic surgery · 2020Trial
- Stable Isotope-Resolved Metabolomics in Elucidating Mitochondrial Metabolic Reprogramming and Therapeutic Targets.Biomedical chromatography : BMC · 2026Review
- Targeting enolase isoenzyme 2 enables precision glycolysis inhibition in VHL-mutant renal cell carcinoma.Cell death & disease · 2026Article
- Overexpression of FTO ameliorates chronic glomerulonephritis by inhibiting glycolysis in glomerular mesangial cells associated with ADPGK mNaunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Transcription Factor ATF4 Deletion Reprograms Glucose Metabolism in Clear Cell Renal Cell Carcinoma.Cancers · 2026Article
- Feasibility and Safety of a Ketogenic Diet During Systemic Therapy for Metastatic Renal Cell Carcinoma: Results from the Cetorein Pilot Study.Nutrients · 2026Article
- An Integrated Immunometabolic Signature Predicts Prognosis and Immunotherapy Response in ccRCC and IdentifiesCancers · 2026Article
- Metformin treatment impairs the adenine nucleotide translocator activity and energy metabolism in human clear cell renal carcinoma cells.Scientific reports · 2026Article
- Emerging roles for the epigenetic modifiers PBRM1 SETD2 and BAP1 in clear cell renal cell carcinoma pathogenesis and prognosis beyond VHL.Discover oncology · 2026Review
- Stable Isotopes for the Study of Energy Nutrient Metabolic Pathways in Relation to Health and Disease.Metabolites · 2026Review
- AATF supports proliferation of glioblastoma cells by sustaining mitochondrial respiration through an NRF-1-dependent mechanism.Cell death & disease · 2026Article
- FUT8 reprograms glycolytic metabolism to promote PKM2 lactylation and drive clear cell renal cell carcinoma progression.Cell death discovery · 2026Article
- Live Metabolomics with NMR.Analytical chemistry · 2026Review
- Metabolic Messengers: Extracellular Vesicles as Central Mediators of Metabolic Reprogramming in Renal Cell Cancer.Biomedicines · 2026Review
- First-in-class HIF-2α therapy in genitourinary oncology: Belzutifan from von Hippel-Lindau disease to advanced renal cell carcinoma.Cancer chemotherapy and pharmacology · 2026Review
- Targeted metabolism creates possibilities for lung cancer treatment in the precision tumor era.Respiratory research · 2026Review
- Why CAR T cell therapy fails in renal cell carcinoma.Frontiers in immunology · 2026Review
- Mitochondrial Dysfunction in Renal Cell Carcinoma: A Comprehensive Review of Pathogenic Mechanisms and Emerging Therapeutic Opportunities.Oncology research · 2026Review
- Obesity-driven metabolic reprogramming and immune dysfunction in renal cancer.Frontiers in immunology · 2026Review
137 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
17 authors at 4 institutions in 1 country.
Kevin D CourtneyDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA; Kidney Cancer Program, University of Texas Southwestern Medical Center, Dallas, TX, USA; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA. Electronic address: kevin.courtney@utsouthwestern.edu.
Divya BezwadaChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Tomoyuki MashimoHarold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA; Annette G. Strauss Center for Neuro-Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Kumar PichumaniAdvanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Vamsidhara VemireddyDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Alexander M FunkAdvanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Jennifer WimberlyDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Sarah S McNeilHarold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA; Annette G. Strauss Center for Neuro-Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Payal KapurKidney Cancer Program, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Yair LotanDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Vitaly MargulisDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Jeffrey A CadedduDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Ivan PedrosaKidney Cancer Program, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Ralph J DeBerardinisChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Craig R MalloyDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA; Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Veterans Affairs North Texas Healthcare System, Dallas, TX, USA.
Robert M BachooDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA; Annette G. Strauss Center for Neuro-Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Elizabeth A MaherDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA; Annette G. Strauss Center for Neuro-Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX, USA. Electronic address: elizabeth.maher@utsouthwestern.edu.
The University of Texas Southwestern Medical Center · USCenter for Neuro-Oncology · USSouthwestern Medical Center · USChildren's Medical Center · US
Funding
University of Texas Southwestern Medical Center SPORE in Kidney CancerP50CA196516 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI James Brugarolas · 2016 to 2026
$24.7MUT Southwestern Center for Translational Medicine (UL1/KL2/TL1)UL1TR001105 · NCATS · UT SOUTHWESTERN MEDICAL CENTER · PI TOTO, ROBERT DANIEL · 2013 to 2017
$24.5MTR&D 3: Imaging Carbohydrate MetabolismP41EB015908 · NIBIB · UT SOUTHWESTERN MEDICAL CENTER · PI BURGESS, SHAWN C · 2012 to 2021
$10.9MMetabolic Regulators of Tumor Growth and ProgressionR35CA220449 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI RALPH J DEBERARDINIS · 2017 to 2026
$9.4MNON-INVASIVE PHYSIOLOGIC PREDICTORS OF AGGRESSIVENESS IN RENAL CELL CARCINOMAR01CA154475 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI PEDROSA, IVAN · 2011 to 2024
$4.3MUT Southwestern Center for Translational Medicine (UL1/KL2/TL1KL2TR001103 · NCATS · UT SOUTHWESTERN MEDICAL CENTER · PI TOTO, ROBERT DANIEL · 2013 to 2017
$4.0MUT Southwestern Center for Translational Medicine (UL18Kl2/TL1)TL1TR001104 · NCATS · UT SOUTHWESTERN MEDICAL CENTER · PI TOTO, ROBERT DANIEL · 2013 to 2017
$418kHoward Hughes Medical InstituteNCATS NIH HHS KL2 TR001103NCATS NIH HHS TL1 TR001104NCATS NIH HHS UL1 TR001105NCI NIH HHS P50 CA196516NCI NIH HHS R01 CA154475NCI NIH HHS R35 CA220449NIBIB NIH HHS P41 EB015908
Abstract
Clear cell renal cell carcinoma (ccRCC) is the most common form of human kidney cancer. Histological and molecular analyses suggest that ccRCCs have significantly altered metabolism. Recent human studies of lung cancer and intracranial malignancies demonstrated an unexpected preservation of carbohydrate oxidation in the tricarboxylic acid (TCA) cycle. To test the capacity of ccRCC to oxidize substrates in the TCA cycle, we infused
Indexed as
AdultAgedCarbon IsotopesCarcinoma, Renal CellCitric Acid CycleGlucoseGlycolysisHumansKidneyKidney NeoplasmsMiddle AgedOxidation-ReductionCarbon IsotopesGlucosecancer metabolismclear cell renal cell carcinomahuman cancerkidney cancermass spectrometrynuclear magnetic resonance spectroscopy (NMR)stable isotope tracing
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.